Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus capecitabine in HER2+ metastatic breast cancer
NCT02422199Phase 2Unknown
- Sponsor
- Hengrui
- Start
- May 2015
- Primary completion
- Oct 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive metastatic breast cancer, sponsored by Hengrui. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02422199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422199.